Long-Term Vision Outcomes in Patients With DME and a Limited Early Visual Response to Ranibizumab in RIDE and RISE.
2020
BACKGROUND AND OBJECTIVE: To compare early and long-term visual responses to ranibizumab in patients with diabetic macular edema. PATIENTS AND METHODS: Retrospective analysis of RIDE (NCT00473382) and RISE (NCT00473330). Vision outcomes over 36 months were compared between limited early gainers (gained /= 10 ETDRS letters) at Month 3. RESULTS: Among 235 ranibizumab-treated patients, 42.6%, 20.0%, and 37.4% were limited early gainers, early 1-line gainers, and early 2-or-more-line gainers, respectively. At Month 36, 71.3% of limited early gainers achieved 6 to 9 and 10 or more ETDRS letter gains. Mean ETDRS letter scores at Month 36 were comparable between limited early gainers (67.8), early 1-line gainers (73.4), and early 2-or-more-line gainers (71.6). CONCLUSION: Clinically meaningful vision outcomes were achieved with long-term ranibizumab treatment, irrespective of early visual acuity response. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:210-218.].
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
15
References
0
Citations
NaN
KQI